PTSD: 11 Facts to Know

(DGIwire) – With approximately eight million adults living with post-traumatic stress disorder (PTSD), according to the U.S. Department of Veterans Affairs, it’s important to know some facts. Here are 11 of them compiled by the VA’s National Center for PTSD.

  1. Just because someone experiences a traumatic event does not mean they have PTSD.
  2. To know whether someone has PTSD, an assessment should be obtained from a clinician.
  3. Sexual assault is more likely to result in symptoms of PTSD than are other types of trauma, including combat.
  4. Social support is one of the greatest protective factors against developing PTSD after trauma.
  5. Research suggests that social support is an even more important resilience factor for women than men.
  6. Trouble sleeping is a core feature of PTSD, so it is important to address sleep problems in PTSD treatment.
  7. Getting help for PTSD early can prevent problems from expanding to other parts of a patient’s life.
  8. Evidence-based treatments for PTSD include psychotherapy (or “counseling”) and medications.
  9. Many people with PTSD also experience chronic pain or other physical health symptoms.
  10. PTSD often co-occurs with depression or other mental health symptoms.
  11. No matter how long it’s been since the trauma, treatment may help.

“We encourage everyone who may be concerned about PTSD to speak with a healthcare professional about potential treatment options. Researchers are studying the safety and effectiveness of new therapies that may one day be able to treat PTSD, including the underserved military-related PTSD population,” says Seth Lederman, MD, the CEO of Tonix Pharmaceuticals, which is developing innovative pharmaceutical products to address public health challenges, with its lead program focusing on PTSD treatments.

Those who were in the military and think they may be affected by PTSD should consider speaking with their doctor about the latest clinical research study involving an investigational new drug as a potential treatment for PTSD, the HONOR study, a Phase 3 clinical research study sponsored by Tonix Pharmaceuticals. At approximately 35 sites across the U.S., about 550 military-related PTSD patients will receive either the investigational new drug, TNX-102 SL* or placebo sublingual tablets, once-daily at bedtime. Based on the encouraging results in an earlier study with TNX-102 SL in a population with military-related PTSD, the U.S. Food and Drug Administration recently granted Breakthrough Therapy designation to TNX-102 SL for the treatment of PTSD.

To protect the subjects’ identities and confidential medical information, the study organizers have obtained a Certificate of Confidentiality from the U.S. Department of Health & Human Services to ensure patients’ identities are shielded from all persons not connected with this clinical research project. The holder of this Certificate of Confidentiality may not be compelled in any Federal, state, or local civil, criminal, administrative, legislative or other proceedings to identify the research subjects.

To see if you or someone you know is pre-qualified to participate in this research study, please access the study website for this ongoing research study, TheHonorStudy.com, and learn more about it at https://clinicaltrials.gov/show/NCT03062540. The HONOR study is open to veterans or those currently serving in any branch of the military or as a military contractor.

Currently there are no satisfactory approved drug treatments for military-related PTSD. The investigational new drug used in the HONOR study represents a new approach to treating the condition. While symptoms of PTSD may improve or worsen while taking part in this study, participation will provide information about the study drug, a new approach to treating PTSD, that might benefit others with the condition in the future.

* TNX-102 SL is an investigational new drug and has not been approved for any indication.

 

Facebook Iconfacebook like buttonTwitter Icontwitter follow button